CYCC RSI Chart
Last 7 days
-0.4%
Last 30 days
15.3%
Last 90 days
-23.9%
Trailing 12 Months
-74.9%
Historical Charts for Stock Metrics
Year | Q1 | Q2 | Q3 | Q4 |
---|---|---|---|---|
2024 | 449.0K | 0 | 0 | 0 |
2023 | 0 | 0 | 0 | 420.0K |
2022 | 0 | 0 | 0 | 0 |
2021 | 0 | 0 | 0 | 0 |
2020 | 0 | 0 | 0 | 0 |
2019 | 0 | 0 | 0 | 0 |
2018 | 0 | 0 | 0 | 150.0K |
2016 | 1.6M | 1.5M | 987.0K | 843.0K |
2015 | 1.9M | 1.8M | 1.8M | 1.9M |
2014 | 1.3M | 1.4M | 1.8M | 1.7M |
2013 | 281.0K | 519.0K | 790.0K | 1.1M |
2012 | 668.0K | 526.0K | 400.0K | 230.0K |
2011 | 258.8K | 405.5K | 552.3K | 699.0K |
2010 | 0 | 0 | 0 | 112.0K |
2009 | 0 | 0 | 0 | 0 |
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
Jan 29, 2024 | schwartz brian | acquired | - | - | 12,500 | interim chief medical officer |
Dec 21, 2023 | mcbarron paul | bought | 6,252 | 3.315 | 1,886 | see remarks |
Dec 21, 2023 | rombotis spiro george | bought | 20,122 | 3.315 | 6,070 | president and ceo |
Jun 30, 2023 | ferguson kenneth m. | acquired | - | - | 21,219 | - |
Jun 30, 2023 | walker karin l | acquired | - | - | 21,219 | - |
Jun 30, 2023 | spiegel robert j. | acquired | - | - | 21,219 | - |
Jun 30, 2023 | schwartz brian | acquired | - | - | 21,219 | - |
Jun 30, 2023 | henney christopher s | acquired | - | - | 21,219 | - |
Jun 30, 2023 | barker sam l | acquired | - | - | 21,219 | - |
Jan 31, 2023 | kirschbaum mark | acquired | - | - | 31,200 | chief medical officer |
Which funds bought or sold CYCC recently?
View All DetailsDatesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
May 15, 2024 | MORGAN STANLEY | unchanged | - | -45.00 | 169 | -% |
May 15, 2024 | Altium Capital Management LP | sold off | -100 | -101,412 | - | -% |
May 15, 2024 | Tower Research Capital LLC (TRC) | added | 418 | 6,682 | 8,837 | -% |
May 15, 2024 | Point72 Asset Management, L.P. | unchanged | - | -8,588 | 32,351 | -% |
May 14, 2024 | Qube Research & Technologies Ltd | unchanged | - | -2.00 | 6.00 | -% |
May 13, 2024 | UBS Group AG | sold off | -100 | -277 | - | -% |
May 13, 2024 | UBS Group AG | new | - | 10,202 | 10,202 | -% |
May 13, 2024 | RENAISSANCE TECHNOLOGIES LLC | added | 44.33 | 5,000 | 44,000 | -% |
May 10, 2024 | OSAIC HOLDINGS, INC. | unchanged | - | -70.00 | 265 | -% |
May 10, 2024 | ACADIAN ASSET MANAGEMENT LLC | reduced | -41.03 | -34,000 | 29,000 | -% |
Unveiling Cyclacel Pharmaceuticals Inc's Major ShareHolders
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Peers (Alternatives to Cyclacel Pharmaceuticals Inc)
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
MRNA | 50.9B | 6.8B | -8.53 | 7.44 | ||||
HILS | 22.5B | 216.3K | -2.5K | 104.0K | ||||
ALNY | 18.9B | 2.0B | -56.9 | 9.43 | ||||
BMRN | 14.7B | 2.5B | 71.65 | 5.96 | ||||
INCY | 12.8B | 3.8B | 17.2 | 3.4 | ||||
MID-CAP | ||||||||
BBIO | 5.6B | 107.9M | -10.31 | 48.09 | ||||
APLS | 5.0B | 524.1M | -12.02 | 9.57 | ||||
AXSM | 3.6B | 251.0M | -12.28 | 14.5 | ||||
ARWR | 3.1B | 240.7M | -6.53 | 12.77 | ||||
ACAD | 2.4B | 813.8M | -1.4K | 3 | ||||
SMALL-CAP | ||||||||
CPRX | 1.9B | 411.3M | 29.91 | 4.73 | ||||
NVAX | 1.8B | 996.6M | -4.58 | 1.83 | ||||
CRBP | 480.9M | 881.7K | -14.25 | 481.06 | ||||
INO | 310.9M | 4.9M | -2.49 | 63.89 | ||||
IBIO | 17.1M | 2.1M | -0.74 | 7.61 |
Cyclacel Pharmaceuticals Inc News
Income Statement (Quarterly) | ||||||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 |
Revenue | -6.5% | 29,000 | 31,000 | 16,000 | 373,000 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Costs and Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 3,168,000 | 2,572,000 | 2,472,000 | 2,424,000 | 2,793,500 | 2,348,000 | 2,337,000 | 2,204,000 |
Operating Expenses | -18.7% | 4,384,000 | 5,391,000 | 6,861,000 | 6,302,000 | 7,319,000 | 8,845,000 | - | - | - | - | - | - | - | - | - | - | - | - | - | 2,337,000 | 2,204,000 |
S&GA Expenses | -15.5% | 1,582,000 | 1,873,000 | 1,625,000 | 1,575,000 | 1,645,000 | 2,143,000 | - | - | - | - | - | - | - | 1,753,000 | 1,497,000 | 1,309,000 | 1,318,000 | 1,363,000 | 1,285,000 | 1,184,000 | 1,192,000 |
R&D Expenses | -20.4% | 2,802,000 | 3,518,000 | 5,236,000 | 4,727,000 | 5,674,000 | 6,702,000 | - | - | - | - | - | - | - | 1,415,000 | 1,075,000 | 1,163,000 | 1,106,000 | 1,430,500 | 1,063,000 | 1,153,000 | 1,012,000 |
EBITDA Margin | 16.8% | -50.55 | -60.76 | -190 | -186 | -182 | -170 | -152 | -149 | -152 | -145 | -125 | -104 | - | - | - | - | - | - | - | - | - |
Interest Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 56,000 | 79,000 |
Income Taxes | -220.9% | -1,354,000 | -422,000 | -668,000 | -586,000 | -1,320,000 | -1,581,000 | - | - | - | - | - | - | - | -378,500 | -281,000 | -286,000 | -290,000 | -448,000 | -273,000 | -307,000 | -268,000 |
Earnings Before Taxes | 24.5% | -4,300,000 | -5,693,000 | -6,700,000 | -6,034,000 | -7,124,000 | -9,000,000 | - | - | - | - | - | - | - | -3,182,000 | -2,537,000 | -2,452,000 | -1,510,000 | -2,752,500 | -2,174,000 | -2,090,000 | -2,110,000 |
EBT Margin | 16.8% | -50.62 | -60.84 | -192 | -188 | -185 | -172 | -154 | -151 | -155 | -147 | -127 | -106 | - | - | - | - | - | - | - | - | - |
Net Income | 44.1% | -2,946,000 | -5,271,000 | -6,032,000 | -5,448,000 | -5,804,000 | -7,419,000 | - | - | - | - | - | - | - | -2,803,500 | -2,256,000 | -2,166,000 | -1,220,000 | -2,304,500 | -1,901,000 | -1,783,000 | -1,842,000 |
Net Income Margin | 18.3% | -43.87 | -53.70 | -164 | -158 | -152 | -141 | -125 | -123 | -127 | -123 | -107 | -91.10 | - | - | - | - | - | - | - | - | - |
Free Cashflow | 87.6% | -483,000 | -3,910,000 | -4,036,000 | -1,305,000 | -6,867,000 | -5,169,000 | -6,968,000 | -1,918,000 | -6,779,000 | -4,551,000 | -6,219,000 | -4,153,000 | - | - | - | - | - | - | - | - | - |
Balance Sheet | ||||||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 |
Assets | -30.0% | 6.00 | 9.00 | 12.00 | 17.00 | 23.00 | 28.00 | 32.00 | 36.00 | 40.00 | 43.00 | 45.00 | 46.00 | 52.00 | 37.00 | 27.00 | 29.00 | 13.00 | 15.00 | 17.00 | 19.00 | 22.00 |
Current Assets | -35.0% | 5.00 | 7.00 | 11.00 | 15.00 | 19.00 | 24.00 | 28.00 | 32.00 | 37.00 | 41.00 | 43.00 | 46.00 | 50.00 | 35.00 | 26.00 | 28.00 | 12.00 | 14.00 | 16.00 | 18.00 | 20.00 |
Cash Equivalents | -17.2% | 3.00 | 3.00 | 6.00 | 10.00 | 11.00 | 18.00 | 24.00 | 29.00 | 30.00 | 37.00 | 40.00 | 44.00 | 48.00 | 33.00 | 23.00 | 25.00 | 9.00 | 12.00 | 13.00 | 15.00 | 18.00 |
Net PPE | -22.2% | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Liabilities | 2.1% | 8.00 | 8.00 | 8.00 | 7.00 | 8.00 | 8.00 | 5.00 | 5.00 | 6.00 | 5.00 | 4.00 | 3.00 | 4.00 | 4.00 | 3.00 | 3.00 | 3.00 | 4.00 | 3.00 | 4.00 | 4.00 |
Current Liabilities | 2.3% | 8.00 | 8.00 | 8.00 | 7.00 | 7.00 | 8.00 | 4.00 | 5.00 | 6.00 | 5.00 | 4.00 | 3.00 | 3.00 | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 | 3.00 | 2.00 |
Shareholder's Equity | -463.4% | -2.21 | 1.00 | 4.00 | 7.00 | 11.00 | 16.00 | 22.00 | 30.00 | 34.00 | 38.00 | 42.00 | 43.00 | 48.00 | 33.00 | 24.00 | 27.00 | 10.00 | 12.00 | 14.00 | 16.00 | 18.00 |
Retained Earnings | -0.7% | -431 | -428 | -423 | -416 | -411 | -405 | -398 | -393 | -388 | -384 | -379 | -374 | -369 | -366 | -363 | -361 | -358 | -357 | -355 | -353 | -351 |
Additional Paid-In Capital | 0.0% | 430 | 430 | 428 | 425 | 423 | 423 | 423 | 424 | 423 | 423 | 422 | 419 | 418 | 400 | 389 | 389 | 370 | 370 | 370 | 370 | 370 |
Shares Outstanding | 24.5% | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | - | - | - | - | - | - | - | - | - |
Float | - | - | - | - | 6.00 | - | - | - | 11.00 | - | - | - | 55.00 | - | - | - | 23.00 | - | - | - | 9.00 | - |
Cashflow (Quarterly) | ||||||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 |
Cashflow From Operations | 87.6% | -483 | -3,910 | -4,036 | -1,305 | -6,861 | -5,169 | -6,968 | -1,915 | -6,775 | -4,549 | -6,210 | -4,215 | -3,566 | -1,152 | -2,129 | -1,846 | -2,807 | -1,117 | -2,011 | -2,635 | -3,684 |
Share Based Compensation | -37.0% | 203 | 322 | 391 | 359 | 401 | 387 | 389 | 350 | 380 | 304 | 320 | 278 | 255 | 141 | 113 | 85.00 | 91.00 | 105 | 183 | 93.00 | 85.00 |
Cashflow From Investing | - | - | - | - | - | -6.00 | - | - | -3.00 | -4.00 | -2.00 | -9.00 | 62.00 | -78.00 | -42.00 | -50.00 | - | -4.00 | 6.00 | -4.00 | -1.00 | 27.00 |
Cashflow From Financing | -107.9% | -79.00 | 999 | -50.00 | -51.00 | -50.00 | 42.00 | 1,532 | 1,474 | -50.00 | 887 | 2,904 | -51.00 | 17,997 | 11,348 | -50.00 | 18,256 | -50.00 | -50.00 | -57.00 | -101 | 4,056 |
CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) | 3 Months Ended | |
---|---|---|
Mar. 31, 2024 | Mar. 31, 2023 | |
Revenues: | ||
Revenues | $ 29,000 | $ 0 |
Operating expenses: | ||
Research and development | 2,802,000 | 5,674,000 |
General and administrative | 1,582,000 | 1,645,000 |
Total operating expenses | 4,384,000 | 7,319,000 |
Operating loss | (4,355,000) | (7,319,000) |
Other income: | ||
Foreign exchange gains (losses) | 1,000 | (87,000) |
Interest income | 2,000 | 116,000 |
Other income, net | 52,000 | 166,000 |
Total other income, net | 55,000 | 195,000 |
Loss before taxes | (4,300,000) | (7,124,000) |
Income tax benefit | 1,354,000 | 1,320,000 |
Net loss | (2,946,000) | (5,804,000) |
Dividend on convertible exchangeable preferred shares | 0 | (50,000) |
Net loss applicable to common shareholders | $ (2,946,000) | $ (5,854,000) |
Basic and diluted earnings per common share: | ||
Net loss per share - diluted | $ (2.27) | $ (7.00) |
Redeemable common shareholders | ||
Basic and diluted earnings per common share: | ||
Net loss per share - diluted | 0 | (7.00) |
Common Stock | ||
Basic and diluted earnings per common share: | ||
Net loss per share - basic | $ (2.27) | $ (7.00) |
Clinical trial supply | ||
Revenues: | ||
Revenues | $ 29,000 | $ 0 |
CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands | Mar. 31, 2024 | Dec. 31, 2023 |
---|---|---|
Current assets: | ||
Cash and cash equivalents | $ 2,798 | $ 3,378 |
Prepaid expenses and other current assets | 2,037 | 4,066 |
Total current assets | 4,835 | 7,444 |
Property and equipment, net | 7 | 9 |
Right-of-use lease asset | 79 | 93 |
Non-current deposits | 1,244 | 1,259 |
Total assets | 6,165 | 8,805 |
Current liabilities: | ||
Accounts payable | 5,200 | 3,543 |
Accrued and other current liabilities | 3,150 | 4,618 |
Total current liabilities | 8,350 | 8,161 |
Lease liability | 21 | 37 |
Total liabilities | 8,371 | 8,198 |
Stockholders' equity: | ||
Common stock, $0.001 par value; 100,000,000 shares authorized at March 31, 2024 and December 31, 2023; 1,318,259 shares issued and outstanding at March 31, 2024 and 1,058,892 shares issued and outstanding at December 31, 2023 | 1 | 1 |
Additional paid-in capital | 429,919 | 429,796 |
Accumulated other comprehensive loss | (898) | (908) |
Accumulated deficit | (431,228) | (428,282) |
Total stockholders' equity | (2,206) | 607 |
Total liabilities and stockholders' equity | 6,165 | 8,805 |
6% Convertible Exchangeable Preferred Stock | ||
Stockholders' equity: | ||
Preferred stock, value | ||
Series A Convertible Preferred Stock | ||
Stockholders' equity: | ||
Preferred stock, value | ||
Series B Convertible Preferred Stock | ||
Stockholders' equity: | ||
Preferred stock, value |